Artículos de revistas
A role for the endocannabinoid system in hepatic steatosis Sistema endocanabinoide y desarrollo de esteatosis hepática
Fecha
2014Registro en:
Revista Medica de Chile, Volumen 142, Issue 3, 2018, Pages 353-360
07176163
00349887
10.4067/S0034-98872014000300010
Autor
Valenzuela, Carina
Castillo, Valeska
Ronco Macchiavello, Ana María
Aguirre, Carolina
Hirsch Birn, Sandra
Llanos Silva, Miguel
Institución
Resumen
The endocannabinoid system (SEC) is an important modulator of several metabolic functions. This system is composed by cannabinoid receptors type 1 and 2 (RCB1 and RCB2), their endogenous ligands, known as endocannabinoids, and the enzymes involved in their synthesis and degradation. A deregulated SEC originates metabolic alterations in several tissues, resulting in the typical manifestations of the metabolic syndrome. Liver steatosis of different origins constitutes a physiopathological condition where an altered hepatic SEC is observed. In this condition, there is an increased expression of RCB1 and/or higher endocannabinoid levels in different hepatic cells, which may exert an autocrine/ paracrine hyperstimulation of RCB1/RCB2. Activation of RCB1 stimulate the expression of several hepatocyte lipogenic factors, thus leading to increased de novo fatty acids synthesis and consequently to an abnormal accumulation of triglycerides. The effect of RCB2 activity on hepatic function is still